DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

ACE inhibitors are widely used drugs in the treatment
of hypertension, congestive heart failure, and diabetic
nephropathy, and they reduce mortality in patients
with a variety of cardiovascular risk factors (Chapter 26).
One effect of ACE inhibitors is to prevent the degradation
of bradykinin. Because bradykinin, by activating
its B 2
receptor, is responsible for many of the beneficial
cardioprotective effects of ACE inhibitors, the search is
on to find a suitable stable B 2
agonist for clinical evaluation.
A major problem for such applications is to
establish a safe therapeutic window between potentially
protecting the heart and avoiding pro-inflammatory
stimulation (Heitsch, 2003).
BIBLIOGRAPHY
Abraham WM, Scuri M, Farmer SG. Peptide and non-peptide
bradykinin receptor antagonists: Role in allergic airway disease.
Eur J Pharmacol, 2006, 533:215–221.
Arrang JM, Garbarg M, Lancelot JC, et al. Highly potent and
selective ligands for histamine H 3
-receptors. Nature, 1987,
327:117–123.
Arrang JM, Morisset S, Gbahou F. Constitutive activity of the
histamine H3 receptor. Trends Pharmacol Sci, 2007,
28:350–357.
Ash ASF, Schild HO. Receptors mediating some actions of histamine.
Br J Pharmacol, 1966, 27:427–439.
Beraldo WT, Andrade SP. Discovery of bradykinin and the
kallikrein-kinin system. In: Farmer SG, ed. The Kinin System.
San Diego, Academic Press, 1997, pp. 1–8.
Best CH, Dale HH, Dudley JW, Thorpe WV. The nature of the
vasodilator constituents of certain tissue extract. J Physiol,
1927, 62:397–417.
Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins:
Kallikreins, kininogens, and kininases. Pharmacol Rev, 1992,
44:1–80.
Biyashev D, Tan F, Chen Z, et al. Kallikrein activates bradykinin
B2 receptors in absence of kininogen. Am J Physiol Heart Circ
Physiol, 2006, 290:H1244–H1250.
Black JW, Duncan WA, Durant CJ, et al. Definition and antagonism
of histamine H 2
-receptors. Nature, 1972, 236:385–390.
Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nat Rev Drug
Discov, 2008, 7:801–802.
Campbell WB, Falck JR. Arachidonic acid metabolites as
endothelium-derived hyperpolarizing factors. Hypertension,
2007, 49:590–596.
Campbell WB, Gebremedhin D, Pratt PF, Harder DR.
Identification of epoxyeicosatrienoic acids as endotheliumderived
hyper-polarizing factors. Circ Res, 1996, 78:415–423.
Campos MM, Leal PC, Yunes RA, Calixto JB. Non-peptide
antagonists for kinin B1 receptors: New insights into their therapeutic
potential for the management of inflammation and
pain. Trends Pharmacol Sci, 2006, 27:646–651.
Clark RA, Sandler JA, Gallin JI, Kaplan AP. Histamine modulation
of eosinophil migration. J Immunol, 1977, 118:
137–145.
Colman RW. Biologic activities of the contact factors in vivo—
Potentiation of hypotension, inflammation, and fibrinolysis,
and inhibition of cell adhesion, angiogenesis and thrombosis.
Thromb Haemost, 1999, 82:1568–1577.
Dale HH. Adventures in Pharmacology. London, Pergamon
Press, 1953.
Dietrich W. Aprotinin: 1 year on. Curr Opin Anaesthesiol, 2009,
22:121–127.
Emami N, Diamandis EP. New insights into the functional mechanisms
and clinical applications of the kallikrein-related peptidase
family. Mol Oncol, 2007, 1:269–287.
Esbenshade TA, Browman KE, Bitner RS, et al. The histamine
H3 receptor: An attractive target for the treatment of cognitive
disorders. Br J Pharmacol, 2008, 154:1166–1181.
Feng DM, DiPardo RM, Wai JM, et al. A new class of bradykinin
B1 receptor antagonists with high oral bioavailability and minimal
PXR activity. Bioorg Med Chem Lett, 2008, 18:682–687.
Ferreira SH, Bartelt DC, Greene LJ. Isolation of bradykininpotentiating
peptides from Bothrops jararaca venom.
Biochemistry, 1970, 9:2583–2593.
Ferry X, Brehin S, Kamel R, Landry Y. G protein–dependent
activation of mast cell by peptides and basic secretagogues.
Peptides, 2002, 23:1507–1515.
Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykininreceptor
blockade on the response to angiotensin-convertingenzyme
inhibitor in normotensive and hypertensive subjects. N
Engl J Med, 1998, 339:1285–1292.
Grossman ML. Some notes on the history of gastrin. In:
Grossman ML, ed. Gastrin. Berkeley, CA, University of
California Press, 1966, pp. 1–7.
Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous
system. Physiol Rev, 2008, 88:1183–1241.
Heitsch H. The therapeutic potential of bradykinin B 2
receptor
agonists in the treatment of cardiovascular disease. Expert
Opin Invest Drugs, 2003, 12:759–770.
Henriksen EJ, Jacob S, Kinnick TR, et al. ACE inhibition and
glucose transport in insulin resistant muscle: Roles of
bradykinin and nitric oxide. Am J Physiol, 1999, 277:
R332–R336.
Hess JF. Molecular pharmacology of kinin receptors. In: Farmer
SG, ed. The Kinin System. San Diego, Academic Press, 1997,
pp. 45–55.
Holgate ST, Canonica GW, Simons FE, et al. Consensus Group
on New-Generation Antihistamines (CONGA): Present status
and recommendations. Clin Exp Allergy, 2003, 33:1305–1324.
Jiang X, Carretero OA, Shesely EG, et al. The kinin B1 receptor
contributes to the cardioprotective effect of angiotensinconverting
enzyme inhibitors and angiotensin receptor blockers
in mice. Exp Physiol, 2009, 94:322–329.
Johnson AR, Erdös EG. Release of histamine from mast cells by
vasoactive peptides. Proc Soc Exp Biol Med, 1973,
142:1252–1256.
Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90
catalyzes activation of the prekallikrein-kininogen complex in
the absence of factor XII. Proc Natl Acad Sci U S A, 2002,
99:896–900.
Kaplan AP. Clinical practice. Chronic urticaria and angioedema.
N Engl J Med, 2002, 346:175–179.
Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin
formation and inflammatory disease. J Allergy Clin Immunol,
2002, 109:195–209.
Kuehn BM. Debate continues over the safety of cold and cough
medicines for children. JAMA, 2008, 300:2354–2356.
933
CHAPTER 32
HISTAMINE, BRADYKININ, AND THEIR ANTAGONISTS